OPEN ACCESS Freely available online

ISSN: 2157-7560
Journal of
Vaccines & Vaccination

Short Communication

Influenza and the Immune Response: Balancing Viral Clearance and Tissue Protection

Carolyn Erickson*

Department of Clinical Microbiology, National Institute of Respiratory Diseases (INER), Mexico City, Mexico

ABOUT THE STUDY

Influenza, a respiratory infection caused by influenza viruses, is responsible for significant morbidity and mortality worldwide. The virus not only challenges the immune system but also inhibits a complex immunopathological response that influences disease severity and outcomes. Understanding the host-virus interactions in influenza is essential for developing more effective therapeutic strategies and vaccines [1].

The immune response to influenza begins with the innate immune system, which includes physical barriers, cellular responses, and soluble mediators. Upon infection, the respiratory epithelium serves as the first line of defense, detecting the virus through Pattern Recognition Receptors (PRRs) such as Toll-Like Receptors (TLRs) and RIG-I-Like Receptors (RLRs) [2-4]. These receptors identify viral components and initiate signaling cascades that lead to the production of type I interferons and other pro-inflammatory cytokines. This early response aims to contain the virus and recruit immune cells to the site of infection.

Neutrophils and macrophages are among the first immune cells to respond. They phagocytose infected cells and release additional cytokines and chemokines to amplify the inflammatory response. While this rapid response is important for controlling the initial viral load, excessive inflammation can damage lung tissue and impair respiratory function. This balance between viral clearance and tissue damage underscores the mixed nature of the immune response to influenza.

Dendritic Cells (DCs) play a pivotal role in linking the innate and adaptive immune responses. They capture viral antigens and migrate to the lymph nodes, where they present these antigens to T cells. This antigen presentation is essential for the activation and differentiation of virus-specific $CD4^+$ and $CD8^+$ T cells [5]. $CD8^+$ T cells, or Cytotoxic T Lymphocytes (CTLs), directly kill infected cells, while $CD4^+$ T cells, or helper T cells, assist in the activation of B cells and the production of virus-specific antibodies.

The adaptive immune response is characterized by its specificity and memory. B cells produce antibodies that neutralize the virus and prevent its spread. Memory T and B cells remain in the body after the infection has been cleared, providing long-term immunity and a more rapid response to subsequent exposures to the virus [6]. However, the high mutation rate of influenza viruses, particularly in the Hemagglutinin (HA) and Neuraminidase (NA) proteins, leads to antigenic drift and shift, which can render previous immune responses less effective and complicate vaccine design.

In severe cases of influenza, the immune response can become dysregulated, leading to a cytokine storm. This hyper inflammatory condition is characterized by the excessive release of cytokines and chemokines, resulting in widespread inflammation, tissue damage, and potentially fatal outcomes [7]. The mechanisms behind cytokine storms are not fully understood, but they highlight the importance of regulating immune responses to balance viral clearance with tissue protection.

Influenza can also exacerbate pre-existing health conditions and lead to secondary bacterial infections. For example, *Streptococcus pneumoniae* and *Staphylococcus aureus* are common bacterial pathogens that can infect the lungs following influenza virus-induced damage to the respiratory epithelium. These secondary infections contribute significantly to the morbidity and mortality associated with influenza, emphasizing the need for comprehensive approaches to manage influenza and its complications [8,9].

Vaccination remains the most effective strategy for preventing influenza infection and its severe consequences. Current vaccines aim to elicit an immune response against the HA and NA proteins of the virus. However, the need for annual vaccine updates due to antigenic control and the sporadic emergence of pandemic strains due to antigenic shift presents ongoing challenges. Research is ongoing to develop universal influenza vaccines that target more conserved viral components, potentially offering broader and longer-lasting protection [10].

Correspondence to: Carolyn Erickson, Department of Clinical Microbiology, National Institute of Respiratory Diseases (INER), Mexico City, Mexico, E-mail: carolyn.erickson@lumc.mx

Received: 01-Apr-2024, Manuscript No. JVV-24-25711; **Editor assigned:** 03-Apr-2024, PreQC No. JVV-24-25711 (PQ); **Reviewed:** 17-Apr-2024, QC No. JVV-24-25711; **Revised:** 24-Apr-2024, Manuscript No. JVV-24-25711 (R); **Published:** 01-May-2024. DOI: 10.35248/2157-7560.24.S26.001

Citation: Erickson C (2024) Influenza and the Immune Response: Balancing Viral Clearance and Tissue Protection J Vaccines Vaccin. S26:001.

Antiviral drugs are another important tool in the management of influenza. Neuraminidase inhibitors, such as oseltamivir and zanamivir, can reduce the severity and duration of symptoms if administered early in the course of infection. However, the development of antiviral resistance necessitates the continuous monitoring of viral strains and the development of new antiviral agents.

CONCLUSION

In summary, the immune response to influenza involves a delicate interplay between viral clearance and immune-mediated tissue damage. Understanding these host-virus interactions is a key to improving preventive and therapeutic measures against influenza. Continued research into the immune mechanisms involved in influenza infection and the development of innovative vaccines and antiviral therapies will be critical in reducing the global impact of this persistent and ever-evolving viral threat.

REFERENCES

1. XOFLUZA (baloxavir marboxil)-Prescribing information. Genentech USA Inc. 2018.
2. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. The Lancet. 2015;385(9979):1729-1737.
3. Venkatesan S, Myles PR, Leonardi-Bee J, Muthuri SG, Al Masri M, Andrews N. Impact of outpatient neuraminidase inhibitor treatment in patients infected with Influenza A (H1N1)pdm09 at high risk of hospitalization: An individual participant data metaanalysis. Clin Infect Dis. 2017;64(10):1328-1334.
4. Hayden FG, Sugaya N, Hirotsu N, Lee N, Hurt AC, Watanabe A. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-924.
5. Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Hama R, Jefferson T. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016;20(42):1-242.
6. Doll MK, Winters N, Boikos C, Kraicer-Melamed H, Gore G, Quach C. Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: A systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017;72(11):2990-3007.
7. Stewart RJ, Flannery B, Chung JR, Gaglani M, Reis M, Zimmerman RK. Influenza antiviral prescribing for outpatients with an acute respiratory illness and at high risk for influenza-associated complications during 5 influenza seasons-United States, 2011-2016. Clin Infect Dis. 2018;66(7):1035-1041.
8. Spagnuolo PJ, Zhang M, Xu Y, Han J, Liu S, Liu J. Effects of antiviral treatment on influenza-related complications over four influenza seasons: 2006-2010. Curr Med Res Opin. 2016;32(8):1399-1407.
9. Wallick C, Wu N, To TM, Keebler D, Moawad D. Antiviral use is associated with a decrease in the rate of influenza-related complications, health care resource utilization, and costs. J Med Econ. 2021;24(1):386-393.
10. Neuberger EE, To TM, Seetasith A, Arndorfer SM, Wallick CJ. Antiviral use and health care use among patients with rheumatoid arthritis and influenza in three influenza seasons, 2016-2019. ACR Open Rheumatology. 2022;4(7):631-639.